Rein Therapeutics, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
RNTX$0.59-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(17,904) | $(21,902) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Commitment fee related to Pre-Paid Advance agreement | 300 | — |
| Original issue discount related to Pre-Paid Advance agreement | 100 | — |
| Depreciation and amortization expense | 1 | 63 |
| Stock-based compensation expense | 1,967 | 984 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (334) | (89) |
| Other assets | — | 2,191 |
| Accounts payable | 3,212 | (111) |
| Operating lease liabilities | — | (48) |
| Accrued expenses and other current liabilities | (3,206) | 1,433 |
| Other long-term liabilities | (277) | — |
| Net cash used in operating activities | (16,141) | (17,479) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock, net of offering costs | 367 | 10,645 |
| Proceeds from Pre-Paid Advances | 1,900 | — |
| Proceeds from issuance of common stock in connection with stock option exercises | 1 | 142 |
| Proceeds from issuance of common stock in connection with warrant exercises | 1,595 | — |
| Proceeds from issuance of warrants, net of offering costs | 481 | 7,030 |
| Proceeds from warrant exchanges, net of offering costs | 2,984 | — |
| Proceeds from warrant exercises with common stock subscribed | 22 | — |
| Net cash provided by financing activities | 7,350 | 17,817 |
| Effect of exchange rate changes on cash and cash equivalents | (26) | 1 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (8,817) | 339 |
| Cash, cash equivalents and restricted cash at beginning of period | 12,865 | 17,338 |
| Cash, cash equivalents and restricted cash at end of period | $4,048 | $17,677 |
| Cash and cash equivalents at end of period | $4,048 | $17,652 |
| Restricted cash at end of period | — | 25 |
| Cash, cash equivalents and restricted cash at end of period | $4,048 | $17,677 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Unrealized (loss) gain on short-term investments | $(33) | $37 |
| Foreign currency translation adjustments | $8 | $— |
| Issuance of common stock for Pre-Paid Advances | $2,011 | $— |
| Conversion of Series X non-voting convertible preferred stock into common stock shares | $— | $46,405 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.